71 related articles for article (PubMed ID: 22722513)
21. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
Langworth S; Bodlund O; Agren H
J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
[TBL] [Abstract][Full Text] [Related]
23. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
24. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
25. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
[TBL] [Abstract][Full Text] [Related]
27. Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
Fava M; Detke MJ; Balestrieri M; Wang F; Raskin J; Perahia D
J Psychiatr Res; 2006 Jun; 40(4):328-36. PubMed ID: 16678205
[TBL] [Abstract][Full Text] [Related]
28. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial.
Tadić A; Wachtlin D; Berger M; Braus DF; van Calker D; Dahmen N; Dreimüller N; Engel A; Gorbulev S; Helmreich I; Kaiser AK; Kronfeld K; Schlicht KF; Tüscher O; Wagner S; Hiemke C; Lieb K
Eur Neuropsychopharmacol; 2016 Apr; 26(4):705-16. PubMed ID: 26899588
[TBL] [Abstract][Full Text] [Related]
29. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
30. Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder.
Raskin J; Xu JY; Kajdasz DK
Int Psychogeriatr; 2008 Apr; 20(2):309-27. PubMed ID: 17588276
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies.
Bhagwagar Z; Torbeyns A; Hennicken D; Zheng M; Dunlop BW; Mathew SJ; Khan A; Weisler R; Nelson C; Shelton R; Thase ME; Lane R
J Clin Psychopharmacol; 2015 Aug; 35(4):454-9. PubMed ID: 25961781
[TBL] [Abstract][Full Text] [Related]
32. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study.
Köhler S; Unger T; Hoffmann S; Steinacher B; Fydrich T; Bschor T
Pharmacopsychiatry; 2013 Mar; 46(2):69-76. PubMed ID: 23093475
[TBL] [Abstract][Full Text] [Related]
33. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
Olgiati P; Serretti A; Souery D; Dold M; Kasper S; Montgomery S; Zohar J; Mendlewicz J
J Affect Disord; 2018 Feb; 227():777-786. PubMed ID: 29254066
[TBL] [Abstract][Full Text] [Related]
34. Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial.
Halaris A; Cantos A; Johnson K; Hakimi M; Sinacore J
J Affect Disord; 2020 Jan; 261():145-152. PubMed ID: 31630035
[TBL] [Abstract][Full Text] [Related]
35. Early switch strategy in patients with major depressive disorder.
Pae CU; Wang SM; Lee SY; Lee SJ
Expert Rev Neurother; 2012 Oct; 12(10):1185-8. PubMed ID: 23082734
[TBL] [Abstract][Full Text] [Related]
36. Early switching strategies in antidepressant non-responders: current evidence and future research directions.
Kudlow PA; McIntyre RS; Lam RW
CNS Drugs; 2014 Jul; 28(7):601-9. PubMed ID: 24831418
[TBL] [Abstract][Full Text] [Related]
37. Optimized regimens of combined medications for the treatment of major depressive disorder: a double-blind, randomized-controlled trial.
Zuilhof Z; Norris S; Blondeau C; Tessier P; Blier P
Neuropsychiatr Dis Treat; 2018; 14():3209-3218. PubMed ID: 30538479
[TBL] [Abstract][Full Text] [Related]
38. Repeated S-ketamine infusions in therapy resistant depression: a case series.
Segmiller F; Rüther T; Linhardt A; Padberg F; Berger M; Pogarell O; Möller HJ; Kohler C; Schüle C
J Clin Pharmacol; 2013 Sep; 53(9):996-8. PubMed ID: 23893490
[No Abstract] [Full Text] [Related]
39. Walking on thin ice: who are we afraid will drown?
Horgan D
Australas Psychiatry; 2012 Oct; 20(5):448. PubMed ID: 23086319
[No Abstract] [Full Text] [Related]
40. A switch in time.
Arcangioli B
Curr Biol; 1992 Jun; 2(6):323-5. PubMed ID: 15335947
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
